Zealand Pharma A/S - American Depositary Shares (ZEAL)
ZEAL moved a median of 0.00% 30 minutes after news, and +0.16% by the close. How ZEAL actually reacts to news — the realized, point-in-time move the market made, measured across 502 labeled events over its full measured history with zero look-ahead.
ZEAL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 205 |
| 30-min | 0.00% | 40% | 257 |
| 60-min | 0.00% | 48% | 268 |
| to close | +0.16% | 53% | 316 |
| Middle 50% of ZEAL reactions | -0.56% to +0.48% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 502 |
Half of all Zealand Pharma A/S - American Depositary Shares news events land between -0.56% and +0.48% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ZEAL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZEAL's baseline. Nothing else.
Recent ZEAL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes | Press release | Business Wire | — | — | |
| OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases | Press release | PR Newswire | — | — | |
| Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide | Press release | GlobeNewswire | — | — | |
| Zealand Pharma Announces Financial Results for the First Quarter of 2024 | Press release | GlobeNewswire | — | — | |
| Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results | Press release | GlobeNewswire | — | — | |
| Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference | Press release | GlobeNewswire | — | — | |
| Zealand Pharma Announces Financial Results for the Full Year 2023 | Press release | GlobeNewswire | — | — | |
| Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis | Press release | GlobeNewswire | — | — | |
| Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results | Press release | GlobeNewswire | — | — | |
| Zealand Pharma major shareholder announcement: J O Hambro Capital Management | Press release | GlobeNewswire | — | — | |
| Zealand Pharma completes registration of capital increase | Press release | GlobeNewswire | — | — | |
| Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion | Press release | GlobeNewswire | — | — | |
| U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility | Press release | GlobeNewswire | — | — | |
| Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank | Press release | GlobeNewswire | — | — | |
| Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome | Press release | GlobeNewswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZEAL section they belong to.
Where else ZEAL is measured.
ZEAL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CORINDUS VASCULAR ROBOTICS INC (CVRS) | 503 | -0.65% | 37% |
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
| Agilent Technologies, Inc. (A) | 498 | +0.01% | 50% |
| ARGOS THERAPEUTICS (ARGS) | 498 | -0.22% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Zealand Pharma A/S - American Depositary Shares's median reaction calculated?
Every labeled ZEAL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 502 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of ZEAL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZEAL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.